RLMD — Relmada Therapeutics Share News
0.000.00%
Last trade - 00:00- $350.94m
- $133.21m
Relmada jumps on positive results from late-stage trial on depression drug
Brief: Relmada Therapeutics Announces Efficacy And Safety Results From The Phase 3 Long-Term Study Of Rel-1017 In Major Depressive Disorder
Brief: Relmada Therapeutics Announces Dosing Of First Patient In Relight, A Phase 3 Trial Of Rel-1017 For The Adjunctive Treatment Of Major Depressive Disorder
Relmada Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Relmada Therapeutics Inc expected to post a loss of 90 cents a share - Earnings Preview
Relmada Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Relmada Therapeutics Reports First Quarter 2023 Financial Results
Relmada Therapeutics Inc expected to post a loss of 89 cents a share - Earnings Preview
Relmada Therapeutics Inc expected to post a loss of 89 cents a share - Earnings Preview
Relmada Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Relmada Therapeutics Reports Fourth Quarter Results
Relmada Therapeutics Inc expected to post a loss of $1.33 a share - Earnings Preview
Relmada Therapeutics Inc expected to post a loss of $1.33 a share - Earnings Preview
Brief: Relmada Therapeutics Holds No Cash Deposits Or Securities At Silicon Valley Bank
Brief: Relmada Therapeutics Appoints Fabiana Fedeli From M&G Investments To Its Board
Brief: Relmada Therapeutics Appoints Cns Therapeutic Expert Cedric O'gorman MD As Chief Medical Officer
U.S. RESEARCH ROUNDUP- Churchill Downs, Mirati Therapeutics, Vivint Smart Home
Relmada slumps as depression therapy fails study
Brief: Relmada Therapeutics Announces Top-Line Results From Phase 3 Reliance I Trial For REL-1017 As Adjunctive Treatment For Major Depressive Disorder